Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.16.7255

Clinicopathological Significance of DLC-1 Expression in Cancer: a Meta-Analysis  

Jiang, Yan (Department of Basic Medical Science, Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University)
Li, Jian-Ming (Department of Basic Medical Science, Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University)
Luo, Huai-Qing (Department of Basic Medical Science, Department of Human Anatomy, Histology and Embryology, Institute of Neuroscience, Changsha Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.16, 2015 , pp. 7255-7260 More about this Journal
Abstract
Background: Recent reports have shown that DLC-1 is widely expressed in normal tissues and is down-regulated in a wide range of human tumors, suggesting it may act as a tumor suppressor gene. We conducted a meta-analysis to determine the correlation between DLC-1 expression and clinicopathological characteristics in cancers. Materials and Methods: A detailed literature search was made for relevant publications from PubMed, EMBASE, Cochrane library databases, Web of Science, CNKI. The methodological quality of the studies was also evaluated. Analyses of pooled data were performed and odds ratios (ORs) were calculated and summarized. Results: Final analysis was performed of 1,815 cancer patients from 19 eligible studies. We observed that DLC- 1 expression was significantly lower in cancers than in normal tissues. DLC-1 expression was not found to be associated with tumor differentiation status. However, DLC-1 expression was obviously lower in advance stage than in early-stage cancers and was more down-regulated in metastatic than non-metastatic cancers. Conclusions: The results of our meta-analysis suggested that DLC-1 expression is significantly lower in cancers than in normal tissues. Aberrant DLC-1 expression may play an important role in cancer genesis and metastasis.
Keywords
DLC-1 expression; metastasis; meta-analysis; cancer;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Guan M, Zhou X, Soulitzis N, et al (2006). Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin Cancer Res, 12, 1412-9.   DOI
2 Heering J, Erlmann P, Olayioye MA (2009). Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration. Exp Cell Res, 315, 2505-14.   DOI
3 Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.   DOI
4 Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60.   DOI
5 Homma Y, Emori Y (1995). A dual functional signal mediator showing RhoGAP and phospholipase C-delta stimulating activities. EMBO J, 14, 286-91.
6 Hua T, Xiaojun Y, Tie Z, et al (2010). The manifestation of DLC- 1 proteins in gastric carcinoma and its clinic-pathological significance. Anhui Med J, 31, 1328-31.
7 Liu JB ZS, Shi MX, Shao BF, Zhang YX (2008). Relationship between methylation status of DLC-1 gene and metastasis of hepatocellular carcinoma. World Chinese J Digestol, 11, 1237-40.
8 McShane LM, Altman DG, Sauerbrei W, et al (2005). Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst, 97, 1180-4.   DOI
9 Mingrui S, Hui C, Xia-yun Z, et al (2014). Expression of DLC-1 and cycfin D1 and their clinical significance in cervical squamous cell carcinoma. Chinese J Diagnostic Pathol, 21, 633-6.
10 Moon SY, Zheng Y (2003). Rho GTPase-activating proteins in cell regulation. Trends Cell Biol, 13, 13-22.   DOI
11 Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.   DOI
12 Duval S,Tweedie R (2000). Trim and fill: A simple funnel-plotbased method of testing and adjusting for publication bias in meta-analysis. Biometrics, 56, 455-63.   DOI
13 Egger M, Davey Smith G, Schneider M, et al (1997). Bias in metaanalysis detected by a simple, graphical test. BMJ, 315, 629-34.   DOI
14 Etienne-Manneville S, Hall A (2002). Rho GTPases in cell biology. Nature, 420, 629-35.   DOI
15 Fan DM, Shi HR (2011). Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase Y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma. Int J Mol Sci, 12, 8489-501.   DOI
16 Fang R, Huirong S, Zhimin C, et al (2012). Protein expression of DLC-1, FAK and Crk-associated 130 kDaP in epithelial ovarian cancer and their significance. Modern Oncol, 21, 152-5.
17 Feng X, Ren C, Zhou W, et al (2014). Promoter hypermethylation along with LOH, but not mutation, contributes to inactivation of DLC-1 in nasopharyngeal carcinoma. Mol Carcinog, 53, 858-70.   DOI
18 Peng D, Ren CP, Yi HM, et al (2006). Genetic and epigenetic alterations of DLC-1, a candidate tumor suppressor gene, in nasopharyngeal carcinoma. Acta Biochim Biophys Sin (Shanghai), 38, 349-55.   DOI
19 Peng H, Long F, Wu Z, et al (2013). Downregulation of DLC-1 gene by promoter methylation during primary colorectal cancer progression. Biomed Res Int, 2013, 181384.
20 Qian X, Li G, Asmussen HK, et al (2007). Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc Natl Acad Sci U S A, 104, 9012-7.   DOI
21 Qin Y, Chu B, Gong W, et al (2014). Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis. J Gastroenterol Hepatol, 29, 964-72.   DOI
22 Quanrui W, Zhimei C (2012). Expression and signiiieance of DLC- 1 protein in gallbladder carcinoma. J Hepatopancreatobiliarv Surg, 24, 214-6.
23 Ren F, Shi H, Zhang G, et al (2013). Expression of deleted in liver cancer 1 and plasminogen activator inhibitor 1 protein in ovarian carcinoma and their clinical significance. J Exp Clin Cancer Res, 32, 60.   DOI
24 Seng TJ, Low JS, Li H, et al (2007). The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene, 26, 934-44.   DOI
25 Steels E, Paesmans M, Berghmans T, et al (2001). Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J, 18, 705-19.   DOI
26 Xue YZ, Wu TL, Wu YM, et al (2013). DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumour Biol, 34, 2857-61.   DOI
27 Tcherkezian J, Lamarche-Vane N (2007). Current knowledge of the large RhoGAP family of proteins. Biol Cell, 99, 67-86.   DOI
28 Wang Y, Lei R, Zhuang X, et al (2014). DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest, 124, 1646-59.   DOI
29 Guan CN, Zhang PW, Lou HQ, et al (2012). DLC-1 expression levels in breast cancer assessed by qRT- PCR are negatively associated with malignancy. Asian Pac J Cancer Prev, 13, 1231-33.   DOI
30 Yam JW, Ko FC, Chan CY, et al (2006). Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res, 66, 8367-72.   DOI
31 Yang C, Tiankang G, Yuntao M, et al (2013a). Expression and clinical significance of DLC-1and MMP-9 in gastric carcinoma. J Ningxia Med University, 35, 872-6.
32 Yang C, Wu D, Jia J, et al (2013b). DLC1 as a regulator of proliferation, invasion, cell cycle, and apoptosis in cutaneous squamous cell carcinoma. Tumour Biol, 34, 2633-43.   DOI
33 Yang X, Popescu NC, Zimonjic DB (2011). DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAPindependent mechanism. Cancer Res, 71, 2916-25.   DOI
34 Yang XY, Guan M, Vigil D, et al (2009). p120Ras-GAP binds the DLC1 Rho-GAP tumor suppressor protein and inhibits its RhoA GTPase and growth-suppressing activities. Oncogene, 28, 1401-9.   DOI
35 Yufei L, Zhaoxiang Z, Lin H, et al (2010). Expression of DLC1 protein and DLC1-mRNA in breast carcinoma and their clinical significance. Chinese J Clin Oncol, 37, 866-9.
36 Yuan BZ, Durkin ME, Popescu NC (2003). Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet, 140, 113-7.   DOI
37 Yuan BZ, Miller MJ, Keck CL, et al (1998). Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res, 58, 2196-9.
38 Yufei L, Shengrong S, Chuan C, et al (2014). Protein expression and promoter methylation of deleted in liver cancer-1 gene in papilarry thyroid carcinoma. Chin J Exp Surg, 31, 152-5.
39 Yujie Z, Qingshuai F, Fangling N, et al (2014). Expressions and clinical significance of DLC1 and ROCK1 in non small cell lung cancer. J Int Oncol, 41, 688-91.
40 Yun F, Huixing Z, Junhong L, et al (2011). Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer. J South Med Univ, 31, 1448-551.
41 Zhang T, Zheng J, Liu C, et al (2009). Expression of DLC-1 in clear cell renal cell carcinoma: prognostic significance for progression and metastasis. Urol Int, 82, 380-7.   DOI
42 Zhefeng Y, Xisheng Y, Bin D, et al (2015). Clinical significance of DLC-1 expression in hepatic cancer. Modern Oncol, 23, 644-6.1